Results · Apr-Jun 2026 · filed 13 Aug 2026
Ipca Laboratories Q1 FY27 results
BlockbusterBlockbuster: sales up 20% or more & profit up 30% or more on the same quarter last year, with a wider operating margin.
Sales grew 21% to ₹2,788 crore from ₹2,309 crore in Apr-Jun 2025.
Operating profit grew 61% to ₹670 crore, an operating margin of 24.0% (up 6.0 points from a year ago).
Net profit grew 82% to ₹424 crore from ₹233 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +17%, net profit +38%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 2,788 | 2,309 | +21% |
| Operating profit (EBITDA) | 669.5 | 416.4 | +61% |
| Operating margin | 24.0% | 18.0% | +6.0 pts |
| Net profit | 424.3 | 232.9 | +82% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 17 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 14 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 14 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 14 Aug 2026Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- 13 Aug 2026Shareholder Meeting / Postal Ballot-Outcome of AGM
- 13 Aug 2026Standalone And Consolidated Unaudited Financial Results For Q1FY27
- 13 Aug 2026Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results For Q1FY27
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.